A "Wish List" Comes True at Matrix
The FDA has been getting tougher on cancer drugs. Lately, it's been asking drugmakers to provide proof not just that their therapies can shrink tumors, but that doing so actually benefits patients--in a way that matters to those patients, not just their doctors. Matrix Pharmaceutical Inc. thinks it got that proof, by asking patients and physicians to choose, before they began participating in its clinical studies, the clinical endpoints they would most like to realize from treatment with IntraDose, a gel-based formulation of the well-known chemotherapeutic agent cisplatin.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.